Direct Cellular Engineering

This week in the Guardrail, we explore how shifting cellular engineering directly inside the human body could eliminate costly manufacturing delays and revolutionize patient access to life-saving treatments. Are you ready to overcome regulatory and delivery hurdles and bring next-generation cell therapies to market faster? Read on.

By Michael Bronfman

August 24, 2026

Traditional cell therapies have achieved extraordinary accomplishments in modern oncology. Chimeric antigen receptor T cell treatments have altered the prognosis for patients suffering from aggressive hematological malignancies like relapsed leukemias, lymphomas, and multiple myeloma. Despite these clinical achievements, the logistical structure of modern cell therapy remains fundamentally constrained.

The current standard of care relies entirely on an autologous ex vivo manufacturing paradigm. Clinicians must harvest T cells from a patient through leukapheresis, transport those living cells to dedicated Good Manufacturing Practice facilities, genetically reprogram them using viral vectors, expand them over several weeks, and deliver them back to the clinical site for reinfusion.

Manufacturing schedules routinely span three to five weeks. This process presents severe bottlenecks. Throughout this waiting window, rapidly progressing disease can cause patient deterioration or mortality before the engineered cells arrive. Intensive labor, stringent quality control, and specialized infrastructure drive treatment prices to hundreds of thousands of dollars per patient, excluding ancillary medical costs for lymphodepleting chemotherapy and prolonged hospital stays.

The Ex Vivo Bottleneck vs The In Vivo Solution

To understand the revolutionary potential of in situ reprogramming, one must examine the structural restrictions inherent to ex vivo cell manufacturing.

Traditional Ex Vivo Pathway

• Patient leukapheresis harvesting

• Transport to a specialized GMP lab

• Viral engineering and gene insertion

• Multi-week ex vivo cellular expansion

• Transport back to clinic and reinfusion following patient lymphodepletion

In Vivo Pathway

• Direct intravenous infusion of targeted vector formulation

• Immediate in situ T cell editing within seconds to hours inside the patient's body

Key Differences in Delivery Logistics

• Cell Processing Requirements: Ex vivo protocols demand complex cell isolation, activation, viral transduction, and extensive expansion steps outside the body. In vivo protocols utilize an off-the-shelf synthetic formulation or targeted vector that requires no patient-specific cell manipulation.

• Therapeutic Turnaround: Traditional manufacturing requires weeks of processing time, during which patients often require bridging therapies to manage disease burden. In vivo vectors can be reconstituted and administered on the same day the treatment decision is made.

• Scale and Health Facilities: Current cell therapies are largely restricted to major academic medical centers that manage cell handling, logistics chain, and complex toxicities. In vivo formulations behave like traditional biologic drugs, opening up administration to regional health centers and community hospitals.

• Cellular Fitness and Stemness: When T cells are harvested, stimulated, and cultured ex vivo for extended durations, they frequently undergo metabolic stress and premature exhaustion. Cells engineered directly inside the living organism retain their natural physiological state, naive phenotypes, and proliferative potential.

Technical Delivery Platforms

Directing genetic material to specific immune cell subsets within a complex systemic environment requires sophisticated delivery systems that can navigate biological barriers without triggering unwanted off-target effects.

Targeted Lipid Nanoparticles

Lipid nanoparticles, similar to those validated during global mRNA vaccine deployment, serve as a non-viral platform for in vivo reprogramming. Standard LNPs naturally accumulate in the liver due to apolipoprotein E adsorption. To redirect these particles specifically toward T lymphocytes, researchers modify the outer lipid shell with targeted ligands, such as monoclonal antibody fragments or single-chain variable fragments that bind surface receptors like CD3, CD4, or CD5.

The structural makeup consists of:

• Outer Shell: Targeted ligands (anti-CD3 or anti-CD5 antibody fragments) and PEGylated lipids for target specificity and stability.

• Internal Core: Ionizable lipids and structural phospholipids surrounding the encapsulated payload.

• Payload: Messenger RNA encoding the CAR construct or CRISPR-Cas editing machinery.

Once administered intravenously, these surface-modified LNPs recognize circulating and tissue-resident T cells and induce receptor-mediated endocytosis. Inside the cell, the ionizable lipids respond to the acidic endosomal environment, damage the membrane, and release the encapsulated messenger RNA into the cytoplasm.

The cytoplasm then translates the mRNA payload into CAR proteins that translocate to the cell membrane. Because mRNA does not integrate into the genomic DNA, expression is transient, lasting from several days to a few weeks. This time-based control offers a major safety advantage, allowing clinicians to titrate dosage and avoid permanently immune-altered states.

Engineered Viral Vectors

For applications requiring permanent genetic integration, researchers are actively refining pseudotyped viral delivery systems. Standard viral vectors, such as adeno-associated viruses or lentiviruses, exhibit broad tropism and infect various cell types indiscriminately.

To overcome this, engineers mutate the native viral envelope proteins to abolish their natural binding capabilities. They then engineer the viral surface to display targeting domains specific to T cell surface markers.

Receptor-targeted lentiviral vectors can selectively transduce CD8-positive cytotoxic lymphocytes or CD4-positive helper lymphocytes directly within lymph nodes and the spleen. This permanent integration guarantees that as the reprogrammed T cells divide in response to tumor antigens, their daughter cells inherit the CAR gene, providing long-term immunological memory.

In Vivo Site-Specific Genomic Editing

A major milestone in cellular engineering is securing precise gene insertion in vivo without random viral integration. Recent developments use dual-vector platforms that combine enveloped delivery vehicles with adeno-associated viruses to execute site-specific knock-ins directly inside endogenous T cells.

The site-specific knock-in mechanism proceeds through distinct biological phases:

• Targeting: Guide RNA directs the Cas9 nuclease to a designated cut site within Exon 1 of the TRAC locus.

• Cleavage: Double-strand DNA breaks are introduced precisely at the target site, knocking out the endogenous T cell receptor.

• Integration: Homology-directed repair templates insert the synthetic CAR gene sequence into the double-strand break point.

• Expression: The integrated CAR gene is transcribed directly under the control of native promoter elements.

Furthermore, conducting this site-specific knockout and knock-in process entirely in vivo preserves T cell stemness. Recent preclinical findings show that T cells engineered inside living tissue express higher levels of stem cell memory markers versus traditional lab-engineered cell products, yielding superior persistence and deeper tumor-clearing capabilities in both hematological and solid tumor models.

Primary Applications and Preclinical Findings

Direct immune cell editing is expanding into wider medical disciplines. Oncology remains the primary target for in vivo CAR technologies.

Hematological Cancers

• Primary Target Indications: Leukemias, Lymphomas, Multiple Myeloma

• Biological Mechanism: Transient or permanent targeting of CD19 or CD20 on malignant B cell populations

Solid Tumors

• Primary Target Indications: Epithelial carcinomas, Glioblastomas

• Biological Mechanism: Multi-antigen targeting combined with microenvironment remodeling factors

Autoimmune Diseases

• Primary Target Indications: Lupus, Rheumatoid Arthritis

• Biological Mechanism: Transient depletion of autoreactive B cells or generation of regulatory T cells

Tissue Fibrosis

• Primary Target Indications: Cardiac scarring, Liver cirrhosis

• Biological Mechanism: Anti-FAP CARs targeting activated fibroblasts to reverse tissue scarring

Hematological and Solid Tumors

In preclinical models, targeted LNPs delivering anti-CD19 CAR mRNA have rapidly generated functional CAR T populations in circulating blood and lymphatic tissue. These in situ generated cells cleared systemic tumor burdens with efficiency matching or exceeding ex vivo controls.

Dual vector gene insertion strategies target the TRAC locus and achieve therapeutic levels of CAR T cells in vivo, successfully clearing aggressive leukemias and multiple myeloma in humanized animal models with a single systemic injection.

Autoimmune and Fibrotic Diseases

The transient nature of non-viral mRNA delivery makes in vivo CAR generation uniquely suited for non-oncology indications where permanent cell modification is unnecessary or hazardous.

• Cardiac and Tissue Fibrosis: Pathological fibrosis in heart disease and liver conditions is driven by overactive, activated fibroblasts expressing Fibroblast Activation Protein. Research using CD5-targeted LNPs carrying anti-FAP CAR mRNA showed that a single systemic infusion could reprogram T cells to selectively eliminate activated fibroblasts, significantly reducing cardiac and hepatic fibrosis and restoring organ function.

• Autoimmune Disorders: In severe autoimmune conditions like systemic lupus erythematosus, transient in vivo depletion of the pathogenic B cell population resets the immune system. Once the transient CAR expression dissipates, naive B cells repopulate the compartment without causing permanent humoral immunodeficiency.

Off-Target Transduction and Tissue Tropism

A central safety requirement for overall vector administration is absolute target specificity. If a viral or nanoparticle vector encapsulates or transduces off-target tissues like hepatocytes, endothelial cells, or healthy parenchymal tissue, the host cells may express chimeric antigen receptors on their surface or suffer unintended genetic editing.

To reduce off-target risks, developers use dual-targeting strategies. This includes combining surface antibody functionalization with cell type-specific promoter sequences, making sure that even if a vector enters a non-immune cell, the synthetic genetic payload remains transcriptionally silent.

Academic References

For additional information about the core mechanisms and translational data of in vivo cellular engineering, refer to the following publications:

• Volta, L. (2026). In vivo generation of CAR T cells: biology, delivery platforms, clinical promise, and translational challenges. Blood Immunology & Cellular Therapy, 2(1), 100027.

• Nyberg, W. A., Bernard, P. L., Ngo, W., et al. (2026). In vivo site-specific engineering to reprogram T cells. Nature, 639, 10235.

• Rurik, J. G., Tombácz, I., Yadegari, A., et al. (2022). CAR T cells produced in vivo to treat cardiac injury. Science, 375(6578), 91-96.

• Klichinsky, M., Ruella, M., Shestova, O., et al. (2020). Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature Biotechnology, 38(8), 947-953.

  To learn more about cellular processing standards and bio manufacturing logistics, explore technical guidelines supplied by the International Society for Cell & Gene Therapy and regulatory insights at the U.S. Food and Drug Administration Cellular & Gene Therapy Products Portal.